Department of Medical Biosciences/Pathology, Umeå University, Umeå, Sweden.
Department of Surgery and Perioperative Sciences/Surgery, Umeå University, Umeå, Sweden.
Breast Cancer Res Treat. 2022 Oct;195(3):367-377. doi: 10.1007/s10549-022-06691-4. Epub 2022 Aug 6.
To investigate if molecular subtype is associated with outcome in stage 1 breast cancer (BC).
Tissue samples from 445 women with node-negative BC ≤ 15 mm, treated in 1986-2004, were classified into surrogate molecular subtypes [Luminal A-like, Luminal B-like (HER2-), HER2-positive, and triple negative breast cancer (TNBC)]. Information on treatment, recurrences, and survival were gathered from medical records.
Tumour subtype was not associated with overall survival (OS). Luminal B-like (HER2-) and TNBC were associated with higher incidence of distant metastasis at 20 years (Hazard ratio (HR) 2.26; 95% CI 1.08-4.75 and HR 3.24; 95% CI 1.17-9.00, respectively). Luminal B-like (HER2-) and TNBC patients also had worse breast cancer-specific survival (BCSS), although not statistically significant (HR 1.53; 95% CI 0.70-3.33 and HR 1.89; 95% CI 0.60-5.93, respectively). HER2-positive BC was not associated with poor outcome despite no patient receiving HER2-targeted therapy, with most of these tumours being ER+.
Stage 1 TNBC or Luminal B-like (HER2-) tumours behave more aggressively. Women with HER2+/ER+ tumours do not have an increased risk of distant metastasis or death, absent targeted treatment.
研究分子亚型是否与 1 期乳腺癌（BC）的预后相关。
对 1986 年至 2004 年治疗的 445 例淋巴结阴性、肿瘤直径≤15mm 的 BC 患者的组织样本进行分类，分为替代分子亚型[Luminal A 样、Luminal B 样（HER2-）、HER2 阳性和三阴性乳腺癌（TNBC）]。从病历中收集治疗、复发和生存信息。
肿瘤亚型与总生存期（OS）无关。Luminal B 样（HER2-）和 TNBC 患者在 20 年时远处转移的发生率更高（风险比（HR）2.26；95%CI 1.08-4.75 和 HR 3.24；95%CI 1.17-9.00）。Luminal B 样（HER2-）和 TNBC 患者的乳腺癌特异性生存率（BCSS）也较差，尽管无统计学意义（HR 1.53；95%CI 0.70-3.33 和 HR 1.89；95%CI 0.60-5.93）。尽管没有患者接受 HER2 靶向治疗，但 HER2 阳性 BC 与不良预后无关，其中大多数肿瘤为 ER+。
1 期 TNBC 或 Luminal B 样（HER2-）肿瘤的侵袭性更强。在没有靶向治疗的情况下，HER2+/ER+肿瘤的患者远处转移或死亡风险没有增加。
